70 likes | 235 Views
Pathology Visions Conference. Digital Pathology HCIT Visions – A GE Healthcare Perspective. Giri Iyer General Manager, Strategic Development Integrated IT Solutions 10/22/2007. Patient Safety: Need better Tox data earlier Drug Efficacy: Need better biomarkers and ADME profiles.
E N D
Pathology Visions Conference Digital Pathology HCIT Visions – A GE Healthcare Perspective Giri Iyer General Manager, Strategic Development Integrated IT Solutions 10/22/2007
Patient Safety: Need better Tox data earlier Drug Efficacy: Need better biomarkers and ADME profiles Drug Candidate Funnel weak Drug Costs and Failure Rates Lost in Translation: Need better data exchange earlier Patient Safety : Five Rights Checking Drug Efficacy: Need better drugs Clinical Care Delivery Pre-Clinical Research Clinical Trial Process A Tale of Two Cities…
The Future of Anatomical Pathology From Glass To Digital From Quasi-quantitative To Dynamic Range From Single Biomarker To Multiplexing To enabling Rx From Dx
Market Adoption Projection Market Access • Scan times • Image Quality • Latency • FDA approval • Workflow • Algorithms • Workflow • ROI story • TCO story Ref Labs driving clinical; AMCs for Clinical Rx adopting first; AMCs for Research only Main stream clinical adoption 2008-2009 2009-2010 2010+ Time
Key Drivers for Industry Success • Whole slide Imaging today.. In vivo molecular imaging tomorrow • Better standards for Interoperability…DICOM, Jpeg, HL7, CDISC, MIMIx?, MIAPE? • FDA compliance vs speed-to-market trade-offs • Better Data Exchange…Fusion between Medical Informatics and Bio Informatics • Ultimate litmus test is Drug Efficacy that is concomitant with Patient Safety
GE HCIT Perspective • Industry evolution driven through image digitization • When its about fast scan times and high resolution images.. GE is a usual suspect • Industry definitions changing? • Is it a PACS? • Is it a LIS? • Is it just the old Anatomic Pathology Module on new steroids? • Interoperability with existing systems is key to success • Customer acceptance will depend upon transforming Pathology workflow with significant value added • Thanks for having us here.. The youngest start-up in the market… much to learn